Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930700 | 1.00 | NPC1 (0.68) | NPC1RAB9AMAPTALDH1A1KDM4E | |
| SCHEMBL29930885 | 0.86 | NPC1 (0.60) | NPC1RAB9AALDH1A1KDM4ESGMS2 | |
| SCHEMBL23611725 | 0.86 | NPC1 (0.60) | NPC1RAB9AALDH1A1KDM4ESGMS2 | |
| SCHEMBL23536856 | 0.86 | PTGER1 (0.60) | NPC1RAB9AMAPTL3MBTL1ATM | |
| SCHEMBL6748166 | 0.84 | SGMS2 (0.72) | NPC1RAB9AMAPTALDH1A1CTSD | |
| SCHEMBL23611714 | 0.83 | SGMS2 (0.58) | NPC1RAB9AMAPTALDH1A1KDM4E | |
| SCHEMBL29930939 | 0.83 | SGMS2 (0.58) | NPC1RAB9AMAPTALDH1A1KDM4E | |
| SCHEMBL4349487 | 0.82 | CTSD (0.72) | NPC1RAB9AMAPTALDH1A1KDM4E | |
| SCHEMBL28862953 | 0.82 | NPC1 (0.56) | NPC1RAB9AMAPTL3MBTL1ATM | |
| SCHEMBL28731423 | 0.81 | HDAC6 (0.57) | NPC1RAB9AMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4085056-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | Berg LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115210229-A | Polycyclic amides as UBE2K modulators for the treatment of cancer | 博格有限责任公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | NPC1 1821/4885RAB9A 1812/4885MAPT 1520/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | NPC1 1821/4885RAB9A 1812/4885MAPT 1520/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | NPC1 1821/4885RAB9A 1812/4885MAPT 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.